Clinical Trials Browser

NIH × Lymphoma, Mantle-Cell × Sirolimus × Clear all

NCT01381692 2021-10-04

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00109967 2014-04-17

CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2 Completed

71 enrolled 10 charts

Lymphoid

Lymphoma, Mantle-Cell

NCT00033267 2014-04-03

CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

Phase 2 Completed

27 enrolled

Lymphoid

Lymphoma, Mantle-Cell